505906487 02/07/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5953204

| SUBMISSION TYPE: | NEW ASSIGNMENT |
|-----------------------|----------------|
| NATURE OF CONVEYANCE: | ASSIGNMENT |

CONVEYING PARTY DATA

| Name | Execution Date |
|----------|----------------|
| ARX, LLC | 05/28/2015 |

RECEIVING PARTY DATA

| Name: | CYNAPSUS THERAPEUTICS INC. |
|-----------------|----------------------------|
| Street Address: | 828 RICHMOND STREET, W. |
| City: | TORONTO |
| State/Country: | CANADA |
| Postal Code: | M6J 1C9 |

PROPERTY NUMBERS Total: 1

| Property Type | Number |
|---------------------|----------|
| Application Number: | 16564864 |

CORRESPONDENCE DATA

Fax Number: (617)428-7045

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (617) 428-0200

Email: patentadmin@clarkelbing.com

Correspondent Name: CLARK & ELBING LLP Address Line 1: 101 FEDERAL STREET

Address Line 2: 15TH FLOOR

Address Line 4: BOSTON, MASSACHUSETTS 02110

| ATTORNEY DOCKET NUMBER: | 50671-020003 |
|-------------------------|-------------------|
| NAME OF SUBMITTER: | JAMES D. DECAMP |
| SIGNATURE: | /James D. DeCamp/ |
| DATE SIGNED: | 02/07/2020 |

Total Attachments: 3

source=Assignment - ARx to Cynapsus#page1.tif source=Assignment - ARx to Cynapsus#page2.tif source=Assignment - ARx to Cynapsus#page4.tif

> **PATENT** REEL: 051756 FRAME: 0115

505906487

Attorney Docket No.: 50671-020001

CONFIRMATORY ASSIGNMENT

WHEREAS, I/We,

ARx, LLC 400 Seaks Run Road Glen Rock, PA 17327 USA

(referred to as "ASSIGNOR"), have right, title, and interest in:

| Title of Application | Filing Date | Serial Number |
|---|----------------|---------------|
| METHODS OF TREATING PARKINSON'S DISEASE BY ADMINISTRATION OF | April 21, 2015 | 62/150,624 |
| APOMORPHINE TO AN ORAL MUCOSA | | |

and for which future applications may be filed, (collectively referred to as the "Application"),

and whereas

Cynapsus Therapeutics Inc. 828 Richmond Street, W. Toronto, Ontario M6J 1C9 Canada

("ASSIGNEE") desires to purchase all of ASSIGNOR's rights in same;

NOW THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration paid by said ASSIGNEE, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR has and by these presents does hereby sell, assign, transfer, and convey unto said ASSIGNEE all of ASSIGNOR's rights, title, and interest in and to said Application, including in and to any conventional, division, continuation, continuation-in-part, substitution, reissue, renewal, reexam, continued prosecution application ("CPA"), or request for continued examination ("RCE") thereof, and in and to all inventions, (herein collectively referred to as "Related U.S. Applications"), preparatory to obtaining Letters Patent of the United States therefor; and ASSIGNOR hereby requests the Commissioner of Patents and Trademarks to issue any and all Letters Patent of the United States resulting from said Application and Related U.S. Applications, to ASSIGNEE, for its interest and for the sole use and benefit of ASSIGNEE and its assigns and legal representatives.

For the same consideration, ASSIGNOR, by these presents does sell, assign, and transfer to ASSIGNEE all of ASSIGNOR's rights, title, and interest in and to any foreign and international applications related to and/or seeking benefit of said Application and Related U.S. Applications, and in and to all inventions (herein collectively referred to as "Related Foreign Applications"), in and to any Letters Patent and similar protective rights granted on said Related Foreign Applications, and in and to the right to claim any applicable priority rights arising from or required for said Related Foreign Applications under the terms of any applicable conventions, treaties, statutes, or regulations, said Related Foreign Applications to be filed and issued in the name of ASSIGNEE or its designee, insolar as permitted by applicable law.

For the same consideration, ASSIGNOR agrees, but at ASSIGNEE's expense, to sign all lawful papers, execute said Application, Related U.S. Applications, and Related Foreign Applications, make all assignments and rightful caths, assist in prosecution of said Application, Related U.S. Applications, and Related Foreign Applications, assist in prosecution of legal proceedings, and generally do everything

Page 1 of 2

Attorney Docket No.: 50671-020001

reasonably possible to aid ASSIGNEE and its successors, assigns, and nominees, to obtain and enforce proper protection of all said inventions in all countries throughout the world.

AND, for the same consideration, ASSIGNOR also hereby sells, assigns, and transfers unto ASSIGNEE all of ASSIGNOR's rights and claims to sue for damages and other remedies with respect to any and all past infringement of all said Application. Related U.S. Applications, and Related Foreign Applications, including said inventions which may have occurred before the date of this Assignment.

| SIGNED this day of | , 20: |
|---|-----------|
| <u>Tadgh Prendeville</u> <u>General Manager, ARx, LLC</u> Name | Signature |
| SIGNED this <u>2877</u> day of <u>1/24</u> | 20_/5_: |
| Anthony Giovinazzo President and CEO, Cynapsus Therapeutics Inc. Name | Signature |

Attorney Docket No.: 50671-020001

reasonably possible to aid ASSIGNEE and its successors, assigns, and nominees, to obtain and enforce proper protection of all said inventions in all countries throughout the world.

AND, for the same consideration, ASSIGNOR also hereby sells, assigns, and transfers unto ASSIGNEE all of ASSIGNOR's rights and claims to sue for damages and other remedies with respect to any and all past infringement of all said Application, Related U.S. Applications, and Related Foreign Applications, including said inventions which may have occurred before the date of this Assignment.

| SIGNED this / day of Tuly | , 20 <u>(</u> 5; |
|---|------------------|
| Tadgh Prendeville General Manager, ARx, LLC Name | Signature |
| SIGNED this day of | ; 20: |
| Anthony Giovinazzo President and CEO, Cynapsus Therapeutics Inc. Name | Signature |